This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
REDWOOD CITY, Calif., June 4, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, will present new data at the upcoming 19
th European Hematology Association (EHA) Congress related to the company's anti-Notch1 (OMP-52M51) clinical-stage program.
At the EHA Congress, OncoMed will present the first data for its proprietary Next Generation DNA Sequencing (NGS) assay developed with MolecularMD (Portland, OR) to identify Notch1 mutation status in patients with certain hematologic malignancies. Notch1 mutations have been linked to more refractory lymphoid malignancies, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and others, putting patients at greater risk for poor outcomes and reduced overall survival. OncoMed's Notch1 mutation biomarker assay is being developed as a companion diagnostic to identify patients whose cancer may be more likely to benefit from treatment with the company's anti-Notch1 antibody, OMP-52M51. OncoMed is currently conducting two separate Phase 1 clinical studies of its Notch1 targeting antibody in patients with certain advanced solid and hematologic tumors, respectively.
The following abstract is available at the
EHA website and has been selected for presentation during the Congress:
Abstract #P861: Development and validation of a Notch1 custom NGS assay for identifying Notch1 mutations in chronic lymphocytic leukemia and other lymphoid malignancies Date and time: Saturday, June 14, 2014 at 5:45 PM – 7:00 PM Session: Chronic lymphocytic leukemia and related disorders - Clinical 2
About Anti-Notch1 (OMP-52M51)
Anti-Notch1 is a first-in-class antibody that selectively targets the Notch1 receptor and prevents signaling through a key signaling pathway in cancer, the Notch pathway. In preclinical models, anti-Notch1 has been shown to have broad-spectrum anti-tumor activity via inhibition of cancer stem cell growth, and promoting cell differentiation, as well as disrupting tumor angiogenesis. Certain lymphoid malignancies and solid tumors have abnormal activation of the Notch1 receptor that can be a key driver of these tumors. Anti-Notch1 is being developed with potential predictive biomarker companion diagnostics.